# IN10018

Source: https://onco.cc/drugs/in10018/  
OnCo record `in10018` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

IN10018 is an experimental small-molecule drug from InxMed (Shanghai) in phase 3 trials for non-small-cell lung cancer, pancreatic ductal adenocarcinoma and ovarian cancer, with its target not yet stated publicly.

## Summary

IN10018 (BI853520) is a small-molecule drug developed by InxMed (Shanghai) and InventisBio. The sponsor describes its target as FAK, which OnCo does not yet have a target page for. The sponsor states: FAK (focal adhesion kinase) inhibitor. ClinicalTrials.gov describes the intervention as: Based on existing clinical data, the RP2D of IN10018 as monotherapy and in combination with chemotherapy, targeted therapy, and immunotherapy is 100 mg QD. For RNK08954 as monotherapy, the Maximum Tolerated Dose (MTD) was not reached during. It is the investigational product in 8 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT07174908 (A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation), in non-small-cell lung cancer, pancreatic ductal adenocarcinoma, ovarian cancer and small-cell lung cancer. The largest, NCT07174908, plans to enrol 400 participants with primary completion expected 2028-09. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Also known as: IN10018 add on to PLD treatment; BI 853520
- Tags: pipeline; ctgov-ingest
- Code: BI853520
- Modality: small molecule
- Mechanism: FAK (focal adhesion kinase) inhibitor.

## Sources

- ClinicalTrials.gov: trials of IN10018: https://clinicaltrials.gov/search?intr=BI853520
- Sponsor page: https://www.inxmed.com

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- targets: [FAK (PTK2)](https://onco.cc/targets/fak/)
- companies: [InventisBio](https://onco.cc/companies/inventisbio/), [InxMed](https://onco.cc/companies/inxmed/)
- trials: [A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation](https://onco.cc/trials/nct07174908/), [A Phase 3 Study of Sosimerasib in Combination With IN10018 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutatio](https://onco.cc/trials/nct07833202/), [a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors](https://onco.cc/trials/nct06166836/), [HX009+ IN10018 With or Without Standard Chemotherapy for Advanced Solid Tumours](https://onco.cc/trials/nct06708663/), [IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC](https://onco.cc/trials/nct05994131/), [IN10018 Combination Therapy in Treatment-naïve ES-SCLC](https://onco.cc/trials/nct06030258/), [IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurren](https://onco.cc/trials/nct06014528/), [IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors](https://onco.cc/trials/nct07441174/), [IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer](https://onco.cc/trials/nct05551507/), [IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer](https://onco.cc/trials/nct05827796/), [Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors](https://onco.cc/trials/nct05379946/)

---
JSON: https://onco.cc/api/v1/entities/in10018.json